← board
NWBO
distress 7/10 · high distress / dilution risk$0.170%today-47% from 52w high
Revenue
pre-revenue
Liquidity
$2M
Runway
0.0 yrs
Shares 1y
+11%
Price & events
-41.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
-10.5%
1M
-10.5%
3M
-41.4%
6M
-34.6%
1Y
-55.3%
2Y
-87.2%
5Y
-89.5%
All
Overview
- Market Cap
- $279.37M
- Enterprise Value
- $337.01M
- Volume
- 3.01M
- 52 Week Range
- $0.15 – $0.32
- Total Shares
- 1.64B
- Float Shares
- 1.61B
- Short %
- 15.09%
- % Held by Insiders
- 4.26%
- % Held by Institutions
- 0.06%
- RVOL
- 0.86x
- Beta
- -0.63
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $1 (+488% upside) · 1 analysts
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-07-20Northwest Biotherapeutics, Inc. (NWBO) Files 8-K Report Detailing Company Information and SEC Compliance - Minichart
- 2026-07-17MHRA says Northwest Biotherapeutics, Inc. (OTCQB: NWBO) DCVax-L filing remains under review - Stock Titan
- 2026-07-08Northwest Biotherapeutics's Newest Presentation Does Not De-Risk The Thesis, But The Story Is Not Over Yet - Seeking Alpha
- 2026-07-08Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses - Yahoo Finance
- 2026-07-02Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting - PR Newswire
- 2026-07-02Northwest Biotherapeutics CTO to present DCVax-L survival analysis Friday - Stock Titan
- 2026-06-27Price to earnings forward of Northwest Biotherapeutics, Inc. – OTC:NWBO - TradingView
- 2026-05-15NORTHWEST BIOTHERAPEUTICS INC 1Q 2026: Revenue $494K, Net income ($3.4M), EPS $0— 10-Q Summary - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.